A01 Vascular endothelial growth factor (VEGF) expression in patients with oral squamous cell carcinoma and its effects on tumor cell growth. Sadhna Aggarwal, All India Institute of Medical Sciences, New Delhi, India.

A02 Nucleolin antagonist peptide N6L, normalizes tumor vasculature by decreasing Ang-2 secretion and inhibits pancreatic ductal adenocarcinoma growth and metastasis. Ilaria Cascone, University of Paris Est, Créteil, France.

A03 Vascular function affected fundamentally different by different antiangiogenic agents. Jon-Vidar Gaustad, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

A04 Is the lack of clinical success with antiangiogenic therapy due to vascular normalization not being a universal phenomenon?. Michael Horsman, Dept. Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.

A05 The anti-angiogenic activity and pharmacokinetic evaluation of a small molecule JFD-WS in preclinical testing. Thanigaivelan Kanagasabai, Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Ft. Lauderdale, FL, United States.

A06 Targeting CAF-derived MFAP5 as a potential antiangiogenic therapy for ovarian cancer. Cecilia Leung, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A07 Knockdown laminin-511 expression blocked endothelial cell function in vitro and angiogenesis in vivo knockout skin model. Jie Li, University of Miami, Miami, FL, United States.

A08 Lymphangiogenesis drives breast tumor cell spread in postpartum women and in models of postpartum breast cancer. Traci Lyons, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A09 Pharmacodynamics of VEGF-targeting therapies using individualized models of cancer. Feilim Mac Gabhann, Johns Hopkins University, Baltimore, MD, United States.

A10 SIMULTANEOUS BLOCK OF ANGIGENESIS THROUGHT PI3K-AMPK/AKT/mTOR SIGNALING PATHWAYS AFTER TRATMENT WITH METFORMIN AND LY294002 IN CANINE MAMMARY TUMOR CELL LINE. Marina Moschetta, FAMERP, São José Do Rio Preto, São Paulo, Brazil.

A11 Radio-sensitivities and angiogenic signaling pathway of irradiated endothelial cells isolated from cancer and normal tissue of human breasts in vitro. Eun-Taex Oh, Inha University College of Medicine, Incheon, Korea, Republic Of.

A12, PR06 Formation of lymph node metastases is not angiogenesis dependent. Timothy Padera, Massachusetts General Hospital, Boston, MA, United States.

A13 Endothelial podosome rosettes regulate vascular branching in tumor angiogenesis. Giorgio Seano, Edwin L. Steele Laboratory for Tumor Biology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States.
A14 Use of VEGF-based splicing-sensitive fluorescent reporters to screen for anti-angiogenic molecules. Eleanor Star, University of Bristol, Bristol, United Kingdom.

A15 Development and characterization of an in vitro co-culture angiogenesis model using hTERT immortalized cells. Chaozhong Zou, ATCC Cell Systems, Gaithersburg, MD, United States.

A16 Semaphorin 3A normalizes the tumor vasculature and impairs cancer progression in a Nrp-1-independent manner. Enrico Giraudo, Candido Cancer Institute -FPO, IRCCS and University of Torino, Candiolo, Italy.

A17 Identification of genetic programs that mediate vascular mimicry in human breast cancer. J. Chuck Harrell, University of North Carolina, Chapel Hill, NC, United States.

A18 Modified ZD6474 (Vandetanib) Derivatives with VEGFR2 and Non-Peptide Integrin Antagonist (IA) Slows Tumor Growth. Yoo-shin Kim, Houston Methodist Research Institute, Houston, TX, United States.

A19 Potent anti-tumor activity of Dll4 blockade in ovarian xenografts mediated by blocking stromal Dll4. Frank Kuhnert, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

A20 EGFL7 mediates potent anti-angiogenic activity through its emilin-like domain. Arun Raturi, University of Alberta, Edmonton, AB, Canada.

A21 Pre-clinical evaluation of the anti-angiogenic efficacy of small molecule Cathepsin L inhibitor KGP94 in prostate and breast cancer models. Dhivya Sudhan, University of Florida, Gainesville, FL, United States.

A22 Identification of novel tumor derived factors that inhibit angiogenesis. Tony Walshe, BERG, Boston, MA, United States.

A23 Development of a therapeutic peptide with anti-tumorigenic, anti-angiogenic and anti-inflammatory activity. Randolph Watnick, Boston Children's Hospital, Boston, MA, United States.

A24 Neuruplin 1 (NRP1) as a Potential Biomarker for Tivozanib + mFOLFOX6 versus Bevacizumab + mFOLFOX6 in Metastatic Colorectal Cancer (mCRC): Post-hoc Biomarker Analysis of BATON-CRC Phase 2 trial. Al Benson, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, United States.

A25 Molecular characterization of cyclin-dependent kinase 1 pathway in newly established epithelial ovarian cancer cell lines. Hanbyoul Cho, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

A26, PR02 Obesity promotes resistance to anti-VEGF therapy in Breast Cancer via pro-inflammatory and angiogenic pathways. Joao Incio, MGH/Harvard Medical School, Boston, MA, United States.
Poster Session A  
March 6, 2015  
12:00 p.m.–3:00 p.m.  
Plaza International Ballroom D/E/F

A27 Imaging and morphometry of tumor angiogenesis and vascular normalization. Moritz Konerding, Institute of Functional and Clinical Anatomy, Johannes Gutenberg-University Mainz, Mainz, Germany.

A28 C-reactive protein as a predictive marker of response to sunitinib treatment in metastatic clear cell renal carcinoma. Martin Pilskog, University of Bergen, Bergen, Norway.

A29, PR05 An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab. Wei Wei, Massachusetts General Hospital, Boston, MA, United States.